Search results
Showing 8236 to 8250 of 8898 results
In development Reference number: GID-TA11511 Expected publication date: TBC
In development Reference number: GID-TA11406 Expected publication date: TBC
In development Reference number: GID-TA11352 Expected publication date: TBC
In development Reference number: GID-TA11491 Expected publication date: TBC
This evidence summary has been updated and replaced by NICE guideline NG28.
Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)
This evidence summary has been updated and replaced by NICE guideline NG17.
Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)
This evidence summary has been updated and replaced by NICE guideline 115.
This evidence summary has been updated and replaced by NICE guideline NG87.
Moderately to severely active ulcerative colitis: adalimumab (ESNM6)
This evidence summary has been replaced by NICE technology appraisal guidance 329.
Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7)
This evidence summary has been updated and replaced by NICE guideline NG217.
Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76)
This evidence summary has been replaced by NICE technology appraisal guidance 486.
Moderate to severe acute post-operative pain: fentanyl transdermal system (ESNM77)
This evidence summary was withdrawn in September 2017 as the medicine is no longer available.
Moderate to severe acute post-operative pain: sufentanil sublingual tablet system (ESNM71)
This evidence summary has been withdrawn because the product is no longer available in the UK.
Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)
This evidence summary has been updated and replaced by NICE guideline 115.
Significant haemorrhage following trauma: tranexamic acid (ESUOM1)
This evidence summary has been updated and replaced by NICE guideline NG39.